United States Contract Development and Manufacturing (CDMO)

Contract Development and Manufacturing (CDMO) Market Size 2026

DataM Intelligence has released a new research report titled “Contract Development and Manufacturing (CDMO) Market Size 2026” The report delivers in-depth insights into key market dynamics, including regional growth trends, market segmentation, CAGR projections, and the revenue performance of leading industry players. It also highlights major growth drivers shaping the market landscape. Designed to provide a clear and comprehensive perspective, the report offers a detailed view of the current market size in terms of both value and volume, along with emerging opportunities and the overall development outlook of the global Contract Development and Manufacturing (CDMO) market.

Connect with Contract Development and Manufacturing (CDMO) Market Decision Makers Today:- https://www.datamintelligence.com/download-sample/contract-development-and-manufacturing-market?sh

United States: Recent Industry Developments
✅ January 2026: Charles River Laboratories expanded its biologics development capabilities through strategic acquisitions, strengthening its integrated CDMO and testing services for advanced therapies.

✅ December 2025: Samsung Biologics increased its U.S. footprint by acquiring a Maryland-based manufacturing facility from GSK, enhancing large-scale biologics production capacity in North America.

✅ December 2025: Thermo Fisher Scientific expanded its U.S. manufacturing network via strategic site acquisitions to strengthen sterile fill-finish and biologics production for global pharma clients.

Download Free Sample Report (Get Higher Priority for Corporate Email ID):- https://datamintelligence.com/download-sample/contract-development-and-manufacturing-market?sh

List of Top Key Players 2026:

Catalent Inc, Recipharm AB, Jubilant Pharmova Limited, Thermo Fisher Scientific Inc., Boehringer Ingelheim International GmbH, IQVIA, Syneos Health, Parexel International (MA) Corporation, Curia Global, Inc., NextPharma Technologies

Growth Forecast Projected (2026):

The Global Contract Development and Manufacturing (CDMO) Market is anticipated to rise at a considerable rate during the forecast period, between 2026 and 2033. In 2025, the market is growing at a steady rate, and with the rising adoption of strategies by key players, the market is expected to rise over the projected horizon.

Key industry Developments 2025-2026:

✅ April 2026: CDMO providers expanded advanced biologics and cell & gene therapy manufacturing capabilities to support rising demand for complex and personalized medicines across global pharma pipelines.

✅ March 2026: Strategic investments increased in high-potency active pharmaceutical ingredient (HPAPI) production facilities, strengthening capacity for oncology and specialty drug manufacturing.

✅ February 2026: Leading CDMOs integrated AI-driven process optimization and digital twins to improve production efficiency, quality control, and regulatory compliance.

✅ January 2026: Expansion of end-to-end service models accelerated, with CDMOs offering integrated drug development, clinical supply, and commercial-scale manufacturing solutions.

✅ December 2025: Partnerships between pharma companies and CDMOs increased to secure long-term manufacturing capacity amid rising demand for biologics and biosimilars.

✅ November 2025: CDMO firms enhanced global footprint through new facility expansions in Asia-Pacific and North America to reduce supply chain risks and improve regional responsiveness.

✅ October 2025: Growing outsourcing trends in pharmaceutical R&D drove increased reliance on CDMOs for formulation development, clinical trial materials, and regulatory support services.

How Our Market Research Process Works 2026-2033:

The global Contract Development and Manufacturing (CDMO) Market research report is developed using a comprehensive combination of primary and secondary data sources. The study evaluates a wide range of industry-influencing factors, including government regulations, evolving market dynamics, competitive intensity, and historical performance trends. It also analyzes technological advancements, emerging innovations, and developments across related industries. In addition, the report assesses market volatility, growth opportunities, potential barriers, and key challenges that could impact the future expansion of the Contract Development and Manufacturing (CDMO) ecosystem.

Latest Mergers & Acquisitions 2025-2026:

Novo Holdings acquisition of Catalent (supporting obesity/GLP-1 manufacturing capacity expansion) – finalized strategic CDMO consolidation move

Thermo Fisher Scientific continued expansion of CDMO/clinical manufacturing platform via multiple acquisitions including Clario deal (up to $9.4B) strengthening end-to-end drug development services

Lonza CDMO restructuring and portfolio optimization following separation of Capsule & Health Ingredients business, signaling focused CDMO pure-play strategy shift
Increasing PE-backed CDMO exits and mid-large scale asset sales driven by improved credit markets and onshoring demand fueling 2026 M&A rebound trend

Growing consolidation in biologics and advanced therapy manufacturing capacity (cell & gene therapy CDMO platforms targeted for acquisition and expansion by large pharma service providers)

Unlock Full 360° Strategic Report: https://www.datamintelligence.com/buy-now-page?report=contract-development-and-manufacturing-market?sh

Japan: Recent Industry Developments
✅ February 2026: Japanese policymakers and industry stakeholders intensified support for domestic CDMO expansion, emphasizing biopharma self-reliance and increased biologics manufacturing capacity.

✅ January 2026: Fujifilm Biotechnologies accelerated its global CDMO expansion strategy, with new large-scale biologics manufacturing investments reinforcing its Japan-linked KojoX production network.

✅ December 2025: Mitsubishi Chemical Group advanced continuous manufacturing capabilities for biologics and cell-based therapies, supporting Japan’s shift toward high-value CDMO outsourcing models.

Major Focused Key Segmentations 2026:

By Service Type: Active Pharmaceutical Ingredient (API) Manufacturing, Finished Dosage Formulation (FDF) Development and Manufacturing, Secondary Packaging

By Research Phase: Pre-Clinical, Phase I, Phase II, Phase III, Phase IV

By End User: Pharmaceutical Companies, Contract Research Organizations (CROs), Generic Pharmaceutical Companies

Regional Growth Analysis for Market (2026):

⇥ North America: Holds the leading position in the CDMO market, driven by strong pharmaceutical outsourcing, advanced biologics manufacturing, and high R&D investment.

⇥ Asia-Pacific (including Japan): Dominates global growth with expanding pharmaceutical production capacity, cost-efficient manufacturing, and rising demand from China, India, and Japan.

⇥ Europe: A major hub for CDMO services supported by strong regulatory frameworks, biopharmaceutical innovation, and established manufacturing networks.

⇥ Middle East & Africa: An emerging CDMO region witnessing gradual expansion through healthcare infrastructure development and increasing pharma investments.

We Provide Benefits of the Report:

Chapter 1: Lays the foundation by defining the scope of the report, highlighting core market segments across regions, product types, and applications. It delivers a clear snapshot of current market size, growth potential, and how the industry is expected to evolve in both the near and long term.

Chapter 2: Spotlights the most impactful market insights, unveiling the transformative trends and forces shaping the future of the industry.

Chapter 3: Provides a deep dive into the competitive landscape of , covering revenue shares, strategic initiatives, and notable mergers & acquisitions that are reshaping the market.

Chapter 4: Presents detailed company profiles of leading players featuring financial performance, product portfolios, profit margins, and key milestones that set them apart in the industry.

Chapters 5 & 6: Break down revenue analysis at both regional and country levels, offering precise data on market size, growth drivers, and expansion opportunities across global markets.

Chapter 7: Analyzes the market by product type, spotlighting segment-specific opportunities and helping stakeholders identify untapped, high-growth areas.

Chapter 8 :Explores the market through application-based segmentation, assessing demand across industries and pinpointing downstream sectors with the strongest potential for growth.

Chapter 9: Maps the industry’s supply chain in detail, tracing upstream and downstream activities to provide clarity on value creation across the ecosystem.

Chapter 10: Wraps up with a concise summary of the report’s key insights distilling the most critical findings and strategic takeaways for decision-makers and stakeholders.

Shape Your Strategy with Market Customization Data: https://datamintelligence.com/customize/contract-development-and-manufacturing-market?sh

FAQ

Q1: What is the current size of the Contract Development and Manufacturing (CDMO) Market?

A: The Contract Development and Manufacturing (CDMO) Market was valued at US$ 150.19 billion in 2024 and is forecasted to hit US$ 280.07 billion by 2033

Q2: How rapidly will the Market expanding?

A: The Contract Development and Manufacturing (CDMO) market is projected to grow at a CAGR of 7.4% between 2025 and 2033.

Get Unlimited Market Reports & Strategic Insights: https://www.datamintelligence.com/reports-subscription?sh

Contact Us –

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us –

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.

Source link

Ardena reaps rewards from CDMO specialization plays, US plant buy

As biotechs face increasingly tight development timelines, scale-up headaches, and, more recently, unpredictable policy fluctuations, one way to stand out as a CDMO partner is by picking a specialty and mastering it. 

That was one of Jeremie Trochu’s goals when he joined as Ardena’s CEO in 2024—aiming to steward the CDMO toward a new phase of growth by expanding its international footprint, refining its strengths and ensuring that recent acquisitions entered the fold smoothly. 

In the ensuing years, Ardena has worked to bolster a range of CDMO capabilities without overloading its clients with potential service offerings, Trochu said in a recent virtual interview with Fierce in tandem with DCAT Week 2026. 

“You want to be holistic, but within a particular specialty,” he explained. 

The CDMO’s current business revolves around its advanced oral solid services, from formulation development through to clinical manufacturing and small-scale commercial production, plus its capabilities related to nanomedicines and advanced conjugates, according to Trochu. 

Ardena has integrated those constituent pieces into its overall focus on precision medicine, specifically working with clients on therapies tailored to smaller patient populations, Trochu continued. 

The CEO speculated that more biotechs are likely looking for one-stop-shop CDMOs such as Ardena given the accelerated development and regulatory timelines they’re operating under in places like the U.S. 

When companies developing drugs for rare or undertreated conditions win FDA fast track or orphan drug designations, the pressure increases “to quickly pivot from successful results in phase 2 all the way through to your commercial launch on an accelerated timeframe,” Trochu explained. 

Newer technologies, such as artificial intelligence, also have the potential to increase the pace of development cycles, he added. 

“If you’re not integrated as an operation, and if you’re not specialized in the capabilities you are offering to your client, you are not going to be able to have the agility and the speed necessary and required by your biotech customers,” Trochu said of the resultant expectations placed on CDMOs.

Breaking down some of Ardena’s recent specialization moves, Trochu homed in on nanomedicine, which he noted the CDMO has been engaged with since “before it was cool,” alluding to the lipid nanoparticles that rose to prominence as delivery vehicles for mRNA in COVID-19 vaccines earlier in the decade. 

Over its history, Ardena has worked on more than 100 nanomedicine programs, by Trochu’s tally, and 30 of those are actively in the clinic now, per the CEO. To support its nanomedicine strategy, Ardena established a facility dedicated to the technology in the Netherlands several years back, he added. 

On the other side of the equation, Ardena hasn’t hesitated to downsize in areas where it feels its resources could be better spent.

Case in point: Earlier this year, Ardena agreed to sell a manufacturing facility in Södertälje, Sweden, to local drugmaker Nanologica for nearly $1 million. As Trochu put it, Ardena was “not in a position to truly invest in the next chapter of growth” at the site.

As for the company’s purpose-built Dutch facility, Trochu said Ardena designed the plant to address a “gap” in the market for nanomedicine developers, pointing out that the site has continued to garner strong international interest from clients despite a strained geopolitical environment. 

“When you have a unique set of capabilities and you have a track record along [with] those capabilities, people from the U.S., people from Asia, definitely people from Europe, will find you,” he said. 

Trochu addressed the recent geopolitical turbulence affecting markets and supply chains directly, noting that while there certainly have been pressures on the biopharma industry, “we’ve been pretty immune to those dynamics.” 

Ultimately, biotech clients are still looking for “best-in-class” partners to help solve their problems, and that desire tends to supersede challenges posed by governmental policy shifts, Trochu said. 

Heading West

For much of its history, Belgium’s Ardena has been “primarily an EU-based CDMO,” Trochu said. But the firm in 2024 made inroads into the U.S. with plans to purchase Catalent’s oral solids development and small-scale manufacturing facility in Somerset, New Jersey, which was put up for sale as part of the U.S. CDMO’s acquisition by Novo Holdings. 

Ardena completed the purchase in February of 2025. 

That timing turned out to be serendipitous, Trochu suggested, as a massive industry push to establish or expand U.S. production infrastructure kicked off soon after, largely in response to the threat of U.S. import tariffs under the Trump administration. 

“If you think about the last 15 to 18 months, it’s even more important to be able to supply clients on both sides of the pond,” he explained.

Trochu admitted that the “timing worked out” on the Catalent facility purchase.

“A year later, it would have been maybe a more competitive process to acquire a world-class GMP facility in the U.S., especially in light of a stronger regionalization trend,” he said. 

Ardena has added around 200 employees to its headcount through the purchase of the site, which is currently equipped for clinical and smaller-scale commercial manufacturing of oral drugs. But from the jump, the company’s strategy was to eventually bring its other capabilities online at the U.S. location, Trochu said. 

Some of those expansion efforts are already underway, with the CDMO’s first bioanalytical lab opening in Somerset soon, the CEO added. Meanwhile, Ardena is eyeing portions of the site’s greater GMP space to devote to nanomedicines in the future, he said. 

Source link